<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04571996</url>
  </required_header>
  <id_info>
    <org_study_id>3112012</org_study_id>
    <nct_id>NCT04571996</nct_id>
  </id_info>
  <brief_title>Blood-Brain Barrier Penetration of Therapeutic Agents in Human</brief_title>
  <acronym>BRIAN</acronym>
  <official_title>Blood-Brain Barrier Penetration of Therapeutic Agents in Human - an Exploratory Repeated Dose Pharmacokinetic Study in Patients With Idiopathic Normal Pressure Hydrocephalus Treated With Cerebroventricular Shunting</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Orion Corporation, Orion Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Orion Corporation, Orion Pharma</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1, open-label, non-randomized, exploratory, repeated dose PK study performed&#xD;
      at a single centre. Up to 6 evaluable subjects are planned. The subjects will receive p.o.&#xD;
      doses of ODM-104 for 5-7 days. Single dose of paracetamol will be administered p.o. together&#xD;
      with ODM-104 for purposes of comparison.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 29, 2020</start_date>
  <completion_date type="Actual">February 23, 2021</completion_date>
  <primary_completion_date type="Actual">February 23, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>Daily PK samples during the first and last day of administration from day 1 to day 5-7</time_frame>
    <description>In plasma / CSF</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax</measure>
    <time_frame>Daily PK samples during the first and last day of administration from day 1 to day 5-7</time_frame>
    <description>In plasma / CSF</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC</measure>
    <time_frame>Daily PK samples during the first and last day of administration from day 1 to day 5-7</time_frame>
    <description>In plasma / CSF</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cav</measure>
    <time_frame>Daily PK samples during the first and last day of administration from day 1 to day 5-7</time_frame>
    <description>In plasma / CSF</description>
  </primary_outcome>
  <primary_outcome>
    <measure>M/P ratio</measure>
    <time_frame>Daily PK samples during the first and last day of administration from day 1 to day 5-7</time_frame>
    <description>In plasma / CSF</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>CNS Disease</condition>
  <arm_group>
    <arm_group_label>ODM-104 and Panadol Zapp</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ODM-104</intervention_name>
    <description>Capsule</description>
    <arm_group_label>ODM-104 and Panadol Zapp</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paracetamol</intervention_name>
    <description>Rapidly dissolving tablet</description>
    <arm_group_label>ODM-104 and Panadol Zapp</arm_group_label>
    <other_name>Panadol Zapp</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Written informed consent (IC) obtained before any study assessments are performed.&#xD;
&#xD;
          2. Sufficient command of the Finnish language to be able to understand the subject&#xD;
             information and to communicate with the study personnel.&#xD;
&#xD;
          3. Males and females over 18 years of age.&#xD;
&#xD;
          4. Body mass index (BMI) between 18-30 kg/m2.&#xD;
&#xD;
          5. Idiopathic normal pressure hydrocephalus.&#xD;
&#xD;
          6. Shunt surgery with cerebroventricular catheter placed at least 3 months earlier.&#xD;
&#xD;
          7. Good general health, based on medical history, physical examination and laboratory&#xD;
             assessments.&#xD;
&#xD;
          8. Adequate mental status to give informed consent as assessed by the investigator and&#xD;
             using the Consortium to Establish a Registry for Alzheimer's Disease (CERAD)&#xD;
             neuropsychological battery.&#xD;
&#xD;
          9. Female participants of child-bearing potential and male participants with female&#xD;
             partners of child-bearing potential must adhere to a highly effective form of&#xD;
             contraception (listed in Section 4.6) from the first study treatment administration&#xD;
             until 1 month after the EoS visit.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Predicted poor compliance with study procedures, restrictions and requirements.&#xD;
&#xD;
          2. Vulnerable subjects (i.e. persons under any administrative or legal supervision).&#xD;
&#xD;
          3. Veins unsuitable for repeated venipuncture or cannulation&#xD;
&#xD;
          4. Evidence of other current clinically significant cardiovascular, renal, hepatic,&#xD;
             haematological, gastrointestinal, pulmonary, metabolicendocrine, neurological,&#xD;
             urogenital or psychiatric disease than iNPH, as judged by the investigator.&#xD;
&#xD;
          5. Type 1 diabetes mellitus.&#xD;
&#xD;
          6. Diagnosis of cancer for which the subject is currently being treated, or for which&#xD;
             there is evidence of active disease. Subjects with local prostate cancer or local&#xD;
             dermatological tumours, such as basal or squamous cell carcinoma, may be included.&#xD;
&#xD;
          7. Susceptibility to severe allergic reactions, e.g. history of anaphylactic shock due to&#xD;
             any reason.&#xD;
&#xD;
          8. Use of medications impacting the metabolism of dopamine, such as other COMT inhibitors&#xD;
             (e.g. entacapone), levodopa and monoamine oxidase (MAO) inhibitors (e.g. rasagiline,&#xD;
             selegiline), within 4 weeks before the first study drug administration.&#xD;
&#xD;
          9. Any clinically significant abnormalities in screening laboratory test results, vital&#xD;
             signs or physical examination findings that might influence the results of the study&#xD;
             or cause a health risk for the subject if he/she takes part in the study.&#xD;
&#xD;
         10. Any clinically significant 12-lead ECG abnormality, such as QTcF &gt; 450 ms, after 10&#xD;
             min rest in supine position at the screening visit.&#xD;
&#xD;
         11. Heart rate (HR) &lt; 50 bpm or &gt; 90 bpm, systolic blood pressure (BP) &lt; 90 mmHg or &gt; 160&#xD;
             mmHg, or diastolic BP &lt; 50 mmHg or &gt; 100 mmHg in supine or seated position after 10&#xD;
             min rest at the screening visit.&#xD;
&#xD;
         12. Positive serology to human immunodeficiency virus antibodies (HIVAgAb), hepatitis C&#xD;
             virus antibodies (HCVAb) or hepatitis B surface antigen (HBsAg).&#xD;
&#xD;
         13. History of alcohol or drug abuse within the last 5 years, or current regular use of&#xD;
             illicit drugs or excessive use of alcohol (regular alcohol drinking of more than 24&#xD;
             units/week for males or 14 units/week for females), or positive breath test for&#xD;
             alcohol or positive urine test for drugs of abuse at screening or prior to the first&#xD;
             IMP administration.&#xD;
&#xD;
         14. Inability to refrain from consuming caffeine-containing beverages during the stay in&#xD;
             the unit.&#xD;
&#xD;
         15. Current use of nicotine-containing products, more than 5 cigarettes or equivalent/day,&#xD;
             or inability to refrain from using nicotine-containing products during the stay at the&#xD;
             study centre.&#xD;
&#xD;
         16. Pregnant or lactating females.&#xD;
&#xD;
         17. Participation in any other clinical drug study within 2 months before the first IMP&#xD;
             administration of this study.&#xD;
&#xD;
         18. Blood donation or loss of significant amount of blood within 2 months prior to the&#xD;
             screening visit.&#xD;
&#xD;
         19. Employee or first-degree relative of an employee of the contract research organization&#xD;
             (CRST) or Orion.&#xD;
&#xD;
         20. Any other condition that in the opinion of the investigator might interfere with the&#xD;
             evaluation of the study results or constitute a health risk for the subject.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Orion Pharma Clinical study director</last_name>
    <role>Study Director</role>
    <affiliation>Orion Corporation, Orion Pharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CRST Turku</name>
      <address>
        <city>Turku</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>September 25, 2020</study_first_submitted>
  <study_first_submitted_qc>September 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2020</study_first_posted>
  <last_update_submitted>April 12, 2021</last_update_submitted>
  <last_update_submitted_qc>April 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Method</keyword>
  <keyword>Blood Brain Barrier</keyword>
  <keyword>Penetration</keyword>
  <keyword>Therapeutics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Central Nervous System Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

